Friday, 13 November 2026European Markets

Coca-ColaEuropacif And INTERPARFUMS Have A High Dividend Yield And Return On Equity In The Consumer Defensive Sector.

Loading stream...

(vianews) - coca-colaeuropacif (ccep.as) is among this list of stock assets with the highest dividend rate and return on equity on the consumer defensive sector.

financial asset price forward dividend yield return on equity
coca-colaeuropacif (ccep.as) €58.90 3.02% 21.88%
interparfums (itp.pa) €60.80 1.83% 21.46%

several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. coca-colaeuropacif (ccep.as)

3.02% forward dividend yield and 21.88% return on equity

coca-cola europacific partners plc, together with its subsidiaries, produces, distributes, and sells a range of non-alcoholic ready to drink beverages. it offers flavours, mixers, and energy drinks; soft drinks, waters, enhanced water, and isotonic drinks; and ready-to-drink tea and coffee, juices, and other drinks. the company provides its products under the coca-cola, diet coke, coca-cola zero sugar, fanta, sprite, monster energy, coca-cola energy, relentless, nalu, urge, burn, kuli, reign, powerade, appletiser, schweppes, finley, mezzo mix, royal bliss, lift, vio schorle, coca-cola signature mixers, nordic mist, smartwater, chaudfontaine, aquarius, vilas del turbon, bonaqua, apollinaris, krystal, honest, costa coffee, fuzetea, chaqwa, nestea, capri-sun, oasis, minute maid, mer, and tropico brands. in addition, it engages in the bottling and other operations. the company was formerly known as coca-cola european partners plc and changed its name to coca-cola europacific partners plc in may 2021. coca-cola europacific partners plc was founded in 1904 and is based in uxbridge, the united kingdom.

earnings per share

as for profitability, coca-colaeuropacif has a trailing twelve months eps of €3.69.

pe ratio

coca-colaeuropacif has a trailing twelve months price to earnings ratio of 15.96. meaning, the purchaser of the share is investing €15.96 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.88%.

more news about coca-colaeuropacif.

2. interparfums (itp.pa)

1.83% forward dividend yield and 21.46% return on equity

interparfums sa designs, manufactures, and distributes perfumes through license agreements with ready-to-wear, jewelry, or accessories houses in france and internationally. the company operates through perfumes and fashion segments. it serves customers under the boucheron, coach, jimmy choo, karl lagerfeld, kate spade, lanvin, montblanc, moncler, rochas, s.t. dupont, van cleef & arpels, and other brand names. the company distributes its products through wholly owned distribution subsidiaries or joint ventures, independent companies, subsidiaries of luxury good corporations, and duty-free operators. interparfums sa was founded in 1982 and is headquartered in paris, france. interparfums sa is a subsidiary of interparfums holding sa.

earnings per share

as for profitability, interparfums has a trailing twelve months eps of €1.51.

pe ratio

interparfums has a trailing twelve months price to earnings ratio of 40.26. meaning, the purchaser of the share is investing €40.26 for every euro of annual earnings.

return on equity

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 21.46%.

more news about interparfums.

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com